Skip to main content

Table 3 Logistic regression analysis of baseline parameters for the improvement of LnRHI (>40%)

From: A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus

Baseline variable

Univariate regression

Multivariate regression using forced inclusion model

OR

95% CI

p

OR

95% CI

p

Age (per year)

1.02

0.94–1.11

0.58

1.05

0.95–1.15

0.33

Gender (male)

2.28

0.54–9.67

0.27

4.22

0.71–25.03

0.11

Body mass index (per 1.0)

1.06

0.83–1.36

0.66

-

-

-

Hemoglobin A1c (per 0.1; %)

0.98

0.89–1.04

0.33

-

-

-

Fasting plasma glucose (per 1.0; mg/dl)

0.98

0.94–1.01

0.17

-

-

-

Total cholesterol (per 1.0; mg/dl)

0.99

0.97–1.03

0.96

-

-

-

LDL cholesterol (per 1.0; mg/dl)

0.98

0.95–1.01

0.21

-

-

-

HDL cholesterol (per 1.0; mg/dl)

1.01

0.96–1.06

0.72

-

-

-

Triglyceride (per 1.0; mg/dl)

1.01

0.99–1.02

0.20

-

-

-

Sulfonylureas (yes)

1.42

0.26–7.76

0.69

-

-

-

Metformin (yes)

1.60

0.34–7.65

0.56

-

-

-

Alpha-glucosidase inhibitor (yes)

0.54

0.11–2.62

0.45

-

-

-

Thiazolidinedione (yes)

0.86

0.07–1.66

0.91

-

-

-

Glinide (yes)

1.00

0.00–---

1.00

-

-

-

DPP4 inhibitor (yes)

0.86

0.07–10.66

0.91

-

-

-

Insulin (yes)

1.74

0.40–7.91

0.45

-

-

-

Ezetimibe-therapy (yes)

4.88

1.01–23.57

0.049

6.42

1.13–36.47

0.036

  1. LnRHI: natural logarithmic transformed value of reactive hyperemia peripheral tonometry index; OR, odds ratio; CI, confidence interval; LDL, low-density lipoprotein; HDL, high-density lipoprotein, DPP-4, dipeptidyl peptidase-4; Hosmer–Lemeshow p = 0.53 in multivariate analysis.